Gaia Gallo
Eli Lilly (United States)(US)Jacksonville University(US)Universidade Estadual Paulista (Unesp)(BR)
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Spondyloarthritis Studies and Treatments, Rheumatoid Arthritis Research and Therapies, Urticaria and Related Conditions
Most-Cited Works
- → Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial(2019)211 cited
- → A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial(2019)168 cited
- → Specialist palliative care improves the quality of life in advanced neurodegenerative disorders: NE-PAL, a pilot randomised controlled study(2015)155 cited
- → Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)(2019)122 cited
- → A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*(2020)112 cited